Health4 months ago
Savara Resubmits MOLBREEVI Application to FDA for Priority Review
Savara (Nasdaq: SVRA) announced on March 11, 2024, that it has resubmitted its biologics license application for MOLBREEVI to the U.S. Food and Drug Administration (FDA)....
